Hybridon Inc. (Amex: HBY - News) announced today two presentations of preclinical data that showed Hybridon's immunomodulatory oligonucleotide (IMO(TM)) compounds inhibited tumor growth in mouse models of cancer. In these preclinical studies IMO monotherapy was shown to inhibit tumor growth in a syngeneic mouse melanoma model. The IMO when combined with Herceptin® in a mouse model of human breast cancer or Rituxan® in mouse models of non-Hodgkin's lymphoma potentiated the effectiveness of both monoclonal antibodies. The presentations were made at the 95th Annual Meeting of the American Association for Cancer Research being held in Orlando FL March 27-31.